Dialog window

Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Dialog window

Jennifer Porter, BA Psychology, MBA – President & CEO

​Having started at Focal Point Research in 2011, Jenn has been fully engaged in the company and since day one, has leveraged her MBA and interest in the regulated products industries to grow her passion for the business and services offered. 

Jenn has excelled at building on initial conversations with a variety of companies from all industries seeking regulatory and quality assurance services. She has developed strong relationships with each client, offering each one a unique opportunity to have the Focal Point Research team help them develop successful strategies and bring products to market, while ensuring their compliance needs are being fulfilled. 

Jenn has not only been a leader internally, but a key contact for all clients and in 2021, Jenn was the obvious choice to lead Focal Point Research into the future as the successor to company founder, Rob Fichtner.

Jennifer balances her career by honouring her wanderlust, spending her leisure time golfing, and enjoying the outdoors with her loving dog.

(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
      • Natural Health Products
      • Topical OTC Drugs
      • Medical Devices
      • Consumer Products
      • FDA Consulting
    • Health Canada Consultants
      • Regulatory Affairs
      • Pharmacovigilance Services
      • MoCRA
      • Ingredient Compliance
      • CEPA
  • Innovation
  • Articles
  • Contact
Select Page
New FDA Draft Guidance: Records Access for Cosmetics Under MoCRA

New FDA Draft Guidance: Records Access for Cosmetics Under MoCRA

by Srishti Chaudhari | Feb 13, 2026 | FDA, MoCRA, U.S. Regulatory

The U.S. Food and Drug Administration (FDA) has released a new draft guidance titled ‘Records Access for Cosmetics’. This publication marks another step in the ongoing implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Purpose and Scope:...
Arizona Introduces SB 1005 to Ban Cosmetic Animal Testing

Arizona Introduces SB 1005 to Ban Cosmetic Animal Testing

by Srishti Chaudhari | Feb 13, 2026 | Uncategorized

The landscape of cosmetic regulation in the United States continues to evolve. The Arizona State Senate has officially introduced SB 1005, a bill that seeks to prohibit the use of animal testing for cosmetic products within the state. If enacted, this legislation...
California DTSC Finalizes MMA Regulation for Nail Products

California DTSC Finalizes MMA Regulation for Nail Products

by Srishti Chaudhari | Feb 13, 2026 | Cosmetics, Cosmetics, U.S. Regulatory, U.S. State Updates

The California Department of Toxic Substances Control (DTSC) has officially finalized new regulations under the Safer Consumer Products (SCP) program, targeting methyl methacrylate (MMA) in nail products. If your company manufactures nail coatings or artificial nails...
FDA Announces Fiscal Year 2026 OMOR Fee Rates: Costs to Increase

FDA Announces Fiscal Year 2026 OMOR Fee Rates: Costs to Increase

by Srishti Chaudhari | Feb 13, 2026 | FDA, OTC Drugs, U.S. Regulatory

The U.S. Food and Drug Administration (FDA) has officially released the fee rates for Over-the-Counter (OTC) Monograph Order Requests (OMOR) for the upcoming Fiscal Year (FY) 2026. As the OTC landscape continues to evolve under the CARES Act reforms, manufacturers and...
FDA Releases Draft Guidance on Mandatory Cosmetics Recalls under MoCRA

FDA Releases Draft Guidance on Mandatory Cosmetics Recalls under MoCRA

by Srishti Chaudhari | Feb 13, 2026 | FDA, MoCRA, U.S. Regulatory

The U.S. Food and Drug Administration (FDA) has published a significant new draft guidance document titled ‘Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry.’ This release is a key step in implementing the Modernization of Cosmetics...
« Older Entries

Recent Posts

  • New FDA Draft Guidance: Records Access for Cosmetics Under MoCRA
  • Arizona Introduces SB 1005 to Ban Cosmetic Animal Testing
  • California DTSC Finalizes MMA Regulation for Nail Products
  • FDA Announces Fiscal Year 2026 OMOR Fee Rates: Costs to Increase
  • FDA Releases Draft Guidance on Mandatory Cosmetics Recalls under MoCRA

Recent Comments

    Archives

    • February 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • June 2025
    • May 2025
    • March 2025
    • October 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • December 2023
    • November 2023
    • September 2023
    • August 2023
    • July 2023
    • June 2023
    • January 2023
    • December 2022
    • November 2022
    • July 2022
    • June 2022
    • April 2022
    • March 2022
    • October 2021
    • July 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • California Cosmetic Regulations
    • California Office of Environmental Health Hazard Assessment
    • Canadian Quality Assurance
    • Canadian Regulatory
    • Cosmetic Ingredient Hotlist
    • Cosmetics
    • Cosmetics
    • Environment and Climate Change Canada
    • European Regulatory
    • Events/Company Updates
    • FDA
    • Federal Plastics Registry
    • Health Canada Updates
    • Importation of NHPs
    • Innovation
    • Medical Device
    • Medical Devices
    • MoCRA
    • Natural Health Products
    • New Mexico
    • OTC Drugs
    • Our View
    • Prop 65
    • Research/Science/Technology
    • Toxic-Free Cosmetics Act
    • U.S. Regulatory
    • U.S. State Updates
    • Uncategorized
    Copyright © 2025 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY